# OUST (OUST) — Financial Analysis

**Exchange:** Unknown  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-06-03  
**Tier:** Free primer (step 2 of 19)  
**Sibling pages:** /stocks/OUST/thesis · /stocks/OUST/memo

## Financial Snapshot

### Step 04 — Financial Statement Quality and Adjustments

**Auditor:** PricewaterhouseCoopers LLP (unqualified FY2024/FY2025; critical audit matter = product revenue recognition) [S1].

---

#### 1. Key Findings

**Net for thesis: mixed, leaning cautious on reported quality — but clean on fraud risk.** Ouster's FY2025 improvement is **real but flattered**: reported revenue, margin, and the "first GAAP-profitable quarter" benefited from **~$22.8M one-time IP royalty** (incl. $16.1M Q4 catch-up) **and ~$8.0M of non-recurring Employee Retention Credits** (ERC) that *reduced* COGS and opex [S1][S2]. The single most important normalization judgment: **SBC of $40.8M (24% of revenue) is a real, recurring economic cost** — Ouster's headline "Adjusted EBITDA positive in Q4 2025" and non-GAAP framing add it back, but on a normalized basis that charges SBC, the company is **still meaningfully loss-making** (Q1 2026 — a clean, royalty-free quarter — was a GAAP net loss of **$(17.5M)** on $48.6M revenue) [S2][S3]. **The clean operating base for valuation:** product revenue ~$147M (FY2025) growing ~30%, normalized product gross margin ~43–46%, opex ~$157M *including* a real ~$40M SBC charge, normalized operating loss ~$(80M) ex-royalty/ex-ERC [S2][S3].

**The mandatory adversarial sweep is reassuring on fraud but flags a genuine legacy-quality history.** **No activist short-seller report (Hindenburg/Muddy Waters/Spruce Point/Citron/etc.) has ever targeted Ouster** [S4] — a positive finding. The real history is **SPAC-era**: a 2021 SEC document subpoena on the de-SPAC S-4's *projected financials*, routine plaintiff-firm "investigations" after the post-SPAC stock decline, legacy Velodyne governance litigation (Moradpour, **settled $27.5M, ~$23.4M insured**), and **material weaknesses in internal controls — now fully remediated (FY2025)** [S5][S6][S7]. None is an active fraud thesis, but together they mean the pre-2024 financials and SPAC-era projections deserve skepticism (relevant to management credibility, Step 08).

#### 2. Implications for Thesis and Valuation

- **Normalize hard before valuing.** Strip the royalty (use product revenue), add back the ERC (~$8M, opex is structurally higher), and **charge full SBC** as a real cost. The result: Ouster is **not yet normalized-profitable** — the "inflection" narrative is ahead of the normalized economics [S2][S3].
- **SBC is the crux of the bull/bear gap.** At 24% of revenue, SBC ≈ the entire operating loss. A bull leans on falling SBC % as revenue scales (it has fallen 69%→36%→24%); a bear notes that adding back $40M/yr of dilutive comp to claim "profitability" is the oldest trick in unprofitable-growth valuation. Step 14/15 must run the DCF **expensing SBC**, not adding it back.
- **The "first profit" is not run-rate.** Q4 2025's $4.0M GAAP net income was royalty-and-ERC-aided; the durable run-rate (Q1 2026) is a ~$(17.5M) quarterly loss. Do not anchor valuation on Q4 2025 [S2][S3].
- **Fraud risk is low; governance/controls risk is fading-but-real.** No short report; PwC unqualified; controls remediated. But the SPAC-era projection subpoena and weak-controls history justify treating management's forward claims with measured skepticism (Step 08) [S5][S6].
- **Legacy litigation is largely behind/insured** — the Moradpour settlement (~$4.1M Ouster net) is immaterial to the thesis [S6].

#### 3. Objective

Convert reported GAAP into an analytically usable, normalized earnings base; test which "one-time" items are truly non-recurring vs. recurring; analyze SBC, impairments, ERC, M&A and lease treatment; flag metric-definition changes; and run the mandatory adversarial research sweep.

#### 4. Narrative Analysis

##### 4.1 GAAP → normalized bridge (the items that distort FY2025)
| Item | FY2025 effect | Recurring? | Normalization |
|---|---|---|---|
| IP-license royalty | +$22.8M revenue (zero COGS) | **No** (one-time; $16.1M Q4 catch-up) | Use **product revenue $146.6M**; royalty inflates GAAP GM (49% vs ~46% non-GAAP product) [S1][S2] |
| Employee Retention Credit (ERC) | ~+$8.0M (reduced COGS $2.4M, R&D $3.3M, S&M $1.1M, G&A $1.2M) | **No** | **Add ~$8M back to opex/COGS** → normalized operating loss ~$8M worse [S1] |
| Stock-based comp | $40.8M (in COGS/opex) | **Yes — real cost** | **Keep as expense**; do NOT add back for intrinsic value [S2] |
| Stereolabs M&A fees | ~$5.9M G&A increase | Mostly one-time | Partial add-back in a normalized opex view [S1] |
| SF office purchase | $22M capex (Dec 2025) | **No** | Normalize FCF: reported FCF $(64.9M) → ~$(43M) ex-office [S2] |
| Goodwill impairment | $166.7M (FY2023) | **No** (non-cash, legacy) | Already excluded from forward view [S8] |
| Velodyne inventory write-down | ~$10M (FY2023) | **No** (legacy) | Excluded [S8] |
| Moradpour settlement accrual | ~$4.1M (Ouster net) | **No** (legacy) | Excluded [S6] |

##### 4.2 The normalized earnings base (for valuation)
- **Revenue base:** product revenue **$146.6M FY2025** (+32%); Q1 2026 run-rate ~$195M annualized [S2][S3].
- **Gross margin:** **product GM ~43–46%** (non-GAAP); GAAP total-co. 49% is royalty-inflated — discard the 49% for forward modeling [S2][S3].
- **Opex:** ~$157M reported, but ~$8M understated by ERC and ~$6M by one-time M&A fees → **normalized opex ~$163M**, of which **~$40M is SBC** [S1][S2].
- **Normalized operating loss FY2025:** reported $(74.0M) → **~$(80–82M)** after removing the royalty's flattering effect and adding back ERC [S1][S2]. The company is **structurally loss-making before SBC is even debated**.
- **Cleanest run-rate quarter:** Q1 2026 (no royalty) — GAAP net loss $(17.5M), adj EBITDA $(6.9M), product GM 43% GAAP / 46% non-GAAP [S3].

##### 4.3 Metric-definition changes to watch
- **Royalty line is new (FY2025)** — creates the oddity that GAAP GM > non-GAAP GM in royalty quarters (royalty has no COGS; non-GAAP strips SBC/amort but not the royalty's margin) [S2].
- **"Sensors shipped for revenue"** is a loose, non-GAAP operational metric (not audited) [S2].
- **Narrative reframing** "eyes of autonomy" (FY2024) → "Physical AI platform" (FY2025) — strategic, not a financial-metric change, but signals a multiple-expansion pitch (note for Step 08/16) [S9].
- **Adjusted EBITDA** add-backs are SBC-heavy — the key definitional caveat [S2].

##### 4.4 Adversarial Research Sweep (mandatory)

**Searches run:** "{Ouster} short seller report / fraud / class action / SEC investigation / material weakness," the activist-shorts name sweep (Hindenburg/Muddy Waters/Citron/Spruce Point/Kerrisdale/Bonitas/J Capital/Viceroy/etc.), and a completeness-gate sweep for 2024–2026 controversies [S4][S5][S6][S7].

| Item | What | Date | Stock impact | Status |
|---|---|---|---|---|
| **Activist short report** | **NONE found** on Ouster (any firm) | — | — | **No short thesis exists** — positive finding [S4] |
| **SEC document subpoena** | Re: projected financial information in the Dec 22, 2020 de-SPAC (Colonnade) **S-4** | Disclosed Aug 2021 | Minor (post-SPAC era) | **No enforcement action; not referenced as active in recent 10-Ks — apparently resolved/dormant** [S5][S7] |
| **Plaintiff-firm "investigations"** | Frank R. Cruz, Scott+Scott, Shareholders Foundation — boilerplate solicitations after post-SPAC decline | Aug–Sep 2021 | Minimal | Routine ambulance-chasing; **no material filed class action against Ouster itself** [S5][S6] |
| **Merger-objection solicitation** | Kaskela Law re: Velodyne acquisition fiduciary duties | Nov 2022 | Minimal | Routine M&A-objection; no material outcome [S6] |
| **Velodyne securities class action (Moradpour)** | Legacy Velodyne disclosure (David Hall founder/board dispute) — inherited via merger | Settled Mar 13, 2024 | n/a (legacy) | **Settled $27.5M; ~$23.4M insured, ~$4.1M Ouster accrual — immaterial; resolved** [S6][S7] |
| **Material weaknesses** | Accounting personnel, segregation of duties, journal entries, IT general/access controls | Identified 2021–2023 | n/a | **Fully remediated as of FY2025** (per 10-K + 2026 proxy) [S6][S9] |
| **2026 proxy: officer exculpation** | New Delaware-law officer-liability shield (Proposal) + request to double authorized shares to 200M | 2026 proxy | n/a | Governance items — note for Step 08/06 (dilution authorization) [S9] |

**Completeness gate:** the final 2024–2026 sweep surfaced **no new short reports, SEC enforcement actions, whistleblower complaints, or material active litigation** — recent coverage is operational. **Conclusion:** Ouster carries **no active fraud/short thesis**; its adversarial history is a **SPAC-era + legacy-Velodyne overhang that is largely resolved/insured and remediated** — a fading quality flag, not a thesis-breaker. [S4][S7]

#### 5. Evidence and Sources
- A clean set of operating numbers now exists for downstream use: **product revenue ~$147M, normalized product GM ~43–46%, opex ~$163M (incl. ~$40M real SBC), normalized operating loss ~$(80M); SBC must be expensed, royalty/ERC excluded** [S1][S2][S3].
- Adversarial sweep complete and documented above [S4–S7].

#### 6. Assumption Register Updates
Added to `OUST_assumption_register.md`:
- **A13** — Normalize FY2025: strip $22.8M royalty (use product rev $146.6M) + add back ~$8M ERC → normalized operating loss ~$(80M). **SBC ($40.8M, 24% of rev) is a REAL recurring cost — DCF must expense it, not add it back.** Cleanest run-rate = Q1 2026 GAAP net loss $(17.5M). *Judgment/Fact.* Sensitivity: High.
- **A14** — No activist short report exists; adversarial history = SPAC-era SEC S-4 subpoena (2021, no action) + plaintiff-firm solicitations + legacy Velodyne Moradpour settlement ($27.5M, mostly insured) + material weaknesses (remediated FY2025). Fading governance/quality overhang, not a fraud thesis. *Fact.* Sensitivity: Medium (Step 08 credibility).

#### 7. Tables and Calculations

##### 7.1 Reported vs normalized (FY2025)
| Metric | Reported | Normalization | Normalized |
|---|---|---|---|
| Revenue | $169.4M | −$22.8M royalty | **$146.6M (product)** |
| Gross margin | 49% GAAP | −royalty benefit | **~43–46% product** |
| Operating loss | $(74.0M) | −royalty GP +~$8M ERC | **~$(80–82M)** |
| SBC | $40.8M | keep as expense | $40.8M (real) |
| Net loss | $(60.4M) | −royalty +ERC | **~$(67–70M)** |
| FCF | $(64.9M) | +$22M office | **~$(43M)** |
[S1][S2]

##### 7.2 SBC trajectory (the dilution cost)
| | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| SBC ($M) | $57.7M | $40.5M | $40.8M |
| SBC % of revenue | 69% | 36% | 24% |
Falling as a %, but **flat in dollars** and still > the operating loss — the core normalization debate [S2][S8].

#### 8. Open Questions and Data Gaps
| Question | Why it matters | Where addressed |
|---|---|---|
| Will any royalty run-rate continue post-catch-up? | FY2026 revenue base | Step 13 |
| SBC trajectory as revenue scales (does $ stay flat or grow?) | Determines normalized profitability path | Step 13 |
| Product-only gross margin precisely, by quarter | Margin model | Step 05 |
| Is the 2021 SEC S-4 matter formally closed? | Tail risk | Step 11 (note as low-probability) |

#### Source Index
| Tag | Document | Section / File | Date | Notes |
|---|---|---|---|---|
| [S1] | OUST FY2025 10-K (MD&A, ERC, royalty, auditor) | `sec_filings/10K_FY2025_summary.md` | 2026-06-02 | Royalty, ERC split, PwC, M&A fees |
| [S2] | SEC XBRL + consolidated KPIs | `xbrl/xbrl_summary.md`, `earnings/press_releases_Q1_2024_to_Q1_2026.md` | 2026-06-02 | SBC, margins, adj EBITDA, GAAP vs non-GAAP |
| [S3] | Q1 2026 results | `presentations/investor_presentation_2025.md`, `earnings/transcript_Q1_2026.md` | 2026-06-02 | Clean run-rate quarter |
| [S4] | Activist-short name sweep | web (Bloomberg, Fortune, Breakout Point, etc.) | 2026-06-03 | No short report on Ouster |
| [S5] | SEC S-4 subpoena (Aug 2021) | web (businessofbusiness, SEC filings) + FY2021 10-K | 2026-06-03 | Projected-financials subpoena |
| [S6] | Litigation (Scott+Scott, Kaskela, Frank Cruz, Moradpour settlement) | web (BusinessWire, GlobeNewswire) | 2026-06-03 | Plaintiff solicitations + $27.5M Velodyne settlement |
| [S7] | Completeness-gate sweep 2024–2026 | web (StockTitan, proxy, SimplyWallSt) | 2026-06-03 | No new material controversies |
| [S8] | OUST FY2023 10-K | `sec_filings/10K_FY2023_summary.md` | 2026-06-02 | Goodwill impairment, inventory write-down |
| [S9] | OUST 2026 DEF 14A | `proxy/governance_and_compensation.md` | 2026-06-02 | Material-weakness remediation, officer exculpation, share authorization |

---

#### Confirmation

- **Step completed:** Step 04 — Financial Statement Quality and Adjustments (incl. mandatory adversarial sweep). **Output:** `Step_04_financial_quality.md`.
- **Key finding:** FY2025's reported improvement is real but **flattered by ~$22.8M one-time royalty + ~$8M ERC**, and the "first profit" is not run-rate. The decisive normalization is that **SBC ($40.8M, 24% of revenue) is a real recurring cost** — charging it, Ouster is still meaningfully loss-making (clean Q1 2026 = $(17.5M) net loss). **Adversarial sweep: NO activist short report on Ouster (positive); the history is SPAC-era + legacy-Velodyne, largely resolved/insured, with material weaknesses now remediated.**
- **Net for thesis:** **Mixed, leaning cautious** on reported quality (normalize hard, expense SBC), **clean on fraud risk.**
- **Thesis tracker:** updated. **Assumption register:** A13 (normalization/SBC), A14 (adversarial) added.
- **Next step:** **Step 05 — Quarterly Momentum and Leading Indicators** — analyze the last 8–12 quarters of revenue/margins/cash flow/shipments, sequential vs YoY trends, inflections, and whether recent quarters confirm or contradict the long-term narrative; and **create `OUST_KPI.md`** (the initial top-10 KPI selection: shipments, ASP, product revenue, gross margin, cash burn, SBC %, geographic mix, etc. — excluding deferred revenue per Step 03b).

**STOP — awaiting user confirmation to proceed to Step 05.**

## Deeper Financial Analysis

The fundamental tier ($1.00) adds 8 dimensions not included here:

- Revenue Breakdown — segment revenue, geographic mix, product-line margins
- Financial Trends — QoQ momentum, leading indicators, inflection points
- Balance Sheet — debt structure, dilution risk, working capital dynamics
- Capital Allocation — ROIC, buyback cadence, reinvestment efficiency
- Earnings Analysis — beats/misses, guidance vs actuals, transcript highlights
- Competitive Positioning — market share, pricing power, peer benchmarks
- Industry Context — TAM, sector tailwinds/headwinds, regulatory backdrop

**API endpoint:** GET /api/v1/research/OUST/fundamental

## Navigation

- Overview: /stocks/OUST
- Financials (this page): /stocks/OUST/financials
- Thesis: /stocks/OUST/thesis
- Investment Memo: /stocks/OUST/memo
- Coverage universe: /stocks